Meningitis B

Meningitis B is a type of bacterial meningitis caused by the Neisseria meningitidis serogroup B bacteria. This serious and potentially life-threatening infection involves inflammation of the protective membranes surrounding the brain and spinal cord. Meningitis B can lead to symptoms such as severe headaches, high fever, neck stiffness, and, in advanced cases, neurological complications. The infection spreads through respiratory droplets and can occur sporadically or in outbreaks, particularly in close-quarters settings such as college campuses. Vaccination, specifically with MenB vaccines, offers a preventive measure against meningitis B, especially in at-risk populations, although it is not yet routinely included in many national immunization programs.

Meningitis B presents with a range of symptoms indicative of inflammation of the protective membranes surrounding the brain and spinal cord. These symptoms include severe headaches, high fever, and neck stiffness. Additionally, individuals may experience sensitivity to light, nausea, vomiting, and, in more advanced cases, neurological complications. The onset of symptoms can be rapid and severe, emphasizing the urgency of prompt medical attention.

Meningitis B is transmitted through respiratory secretions, including coughing, sneezing, and close contact with an infected person. The bacteria can spread from person to person in crowded environments, such as dormitories or households. Additionally, activities that involve close personal contact, like kissing or sharing utensils, can contribute to transmission.

The diagnosis of Meningitis B involves a combination of clinical evaluation and laboratory testing. Healthcare professionals assess symptoms such as severe headaches, fever, and neck stiffness. A definitive diagnosis is typically confirmed through cerebrospinal fluid analysis obtained via a lumbar puncture. Laboratory tests, including polymerase chain reaction (PCR) and culture, help identify the Neisseria meningitidis serogroup B bacteria responsible for the infection.

Preventing Meningitis B primarily involves vaccination, and available vaccines specifically targeting Neisseria meningitidis serogroup B have been developed. These vaccines are recommended for individuals at increased risk, such as college students living in communal settings. Maintaining good personal hygiene practices, including proper handwashing and avoiding close contact with individuals exhibiting symptoms, can also contribute to prevention. Timely administration of post-exposure prophylaxis to close contacts of confirmed cases is crucial in curbing potential outbreaks.

The treatment of Meningitis B typically involves hospitalization and the prompt administration of appropriate antibiotics, such as intravenous ceftriaxone or cefotaxime. Supportive care, including measures to alleviate symptoms and maintain hydration, is an integral part of the treatment plan. In severe cases, individuals may require intensive care and monitoring. Early diagnosis is crucial, and treatment should be initiated urgently upon suspicion of the infection to improve outcomes and reduce the risk of complications.

  • The United Kingdom led the global initiative by becoming the first country to implement a comprehensive national immunization program featuring the Bexsero vaccine for meningitis B.

  • The majority of meningitis infections tend to occur during the winter months.

  • Meningitis can lead to lasting complications, including hearing loss, vision impairment, seizures, limb amputation, and brain damage.


Select your destination to book your travel vaccination.

Find Destination